Presentation Thank you very much, and good day, everyone. I'd like to welcome everyone to our call today for a discussion around a very important new collaboration between Nurix and Roche centered on the development and commercialization of bexobrutideg, our potentially best-in-class BTK degrader for B-cell malignancies and autoimmune disease. I would now like to turn the conference over to our host, Arthur Sands, President and CEO. Arthur, you may begin. We will be making certain forward-looking statements ...